The news is directly related to Revolution Medicines and is likely to influence investor sentiment. While the Overweight rating suggests that JP Morgan expects the stock to outperform, the reduction in price target may create some uncertainty. However, the impact on the stock price is not clear cut and could be neutral in the short term.